Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Baxter
AstraZeneca
Mallinckrodt
Merck

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,394,826

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,394,826
Title:Dual mechanism inhibitors for the treatment of disease
Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
Inventor(s): deLong; Mitchell A. (Chapel Hill, NC), Sturdivant; Jill Marie (Chapel Hill, NC), Royalty; Susan M. (Cary, NC)
Assignee: Aerie Pharmaceuticals, Inc. (Research Triangle Park, NC)
Application Number:12/694,965
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 8,394,826

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Aerie Pharms Inc RHOPRESSA netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208254-001 Dec 18, 2017 RX Yes Yes   Start Trial   Start Trial Y Y REDUCTION OF ELEVATED INTRAOCULAR PRESSURE   Start Trial
Aerie Pharms Inc ROCKLATAN latanoprost; netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208259-001 Mar 12, 2019 RX Yes Yes   Start Trial   Start Trial Y Y REDUCTION OF ELEVATED INTRAOCULAR PRESSURE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
AstraZeneca
Moodys
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.